Clinical Trials Logo

Airway Remodeling clinical trials

View clinical trials related to Airway Remodeling.

Filter by:

NCT ID: NCT04365205 Recruiting - Asthma Clinical Trials

Effect of Benralizumab on Airway Remodeling in Asthma

BENRAMOD
Start date: September 23, 2020
Phase:
Study type: Observational

The anti-interleukin (IL)-5 receptor benralizumab inhibits eosinophilic inflammation but its potential effect on airway remodeling remains unknown. The main objective of this study is to assess the effect of benralizumab in an in vitro model of airway remodeling using cells obtained from asthmatic patients.

NCT ID: NCT03842839 Recruiting - Airway Remodeling Clinical Trials

Effect of Tiotropium on Airway Remodeling in Patients With Early Stage COPD Accessed by Optical Coherence Tomography

Start date: October 1, 2018
Phase: N/A
Study type: Interventional

The study aims to explore the effect of tiotropium on airway remodeling by using Endobronchial Optical Coherence Tomography (EB-OCT). We enrolled patients with GOLD I stage COPD. All the patients will be divided into four groups randomly to receive SABA as needed with or without regular use of tiotropium. Changes of airway morphology (accessed by EB-OCT), pulmonary function, QOL, and SABA usage will be obtained.

NCT ID: NCT03797404 Completed - Asthma Clinical Trials

Airway Remodeling During Mepolizumab Treatment

REMOMEPO
Start date: April 24, 2019
Phase:
Study type: Observational [Patient Registry]

Chronic airway changes, such as smooth muscle hypertrophy/hyperplasia, reticular basement membrane (RBM) thickening, goblet cells hyperplasia characterize severe asthma. Chronic inflammation, and especially eosinophilia and T2 cytokines are involved in these structural changes. The aim of this prospective observational study is to assess airway changes, assessed by bronchial biopsies before treatment, then after 6 months and 12 months, induced by mepolizumab in 40 severe asthma patients who will receive the treatment as part of their standard care. Changes in RBM thickening, in airway smooth muscle (ASM) area, in the number of PGP9 sections will be assessed on bronchial biopsies after 6 months and 12 months of mepolizumab treatment. Bronchoalveolar lavage (BAL) levels of inflammatory and remodeling mediators and of extra-cellular matrix (ECM) components will be measured after 6 months and 12 months of mepolizumab treatment. Relationship between clinical response to mepolizumab and remodeling changes after 6 months and 12 months will be assessed.

NCT ID: NCT03388359 Recruiting - Allergic Asthma Clinical Trials

Role of Extracellular Matrix in the Development of Airway Remodeling in Asthma

ECMA
Start date: June 1, 2017
Phase: N/A
Study type: Interventional

Asthma is a major noncommunicable chronic inflammatory disorder which is characterized by airway inflammation and related to pathological modifications of the bronchial wall structure so called airway remodeling. Airway remodeling seen in asthma is mainly described by epithelial changes, subepithelial fibrosis, increased airway smooth muscle (ASM) mass, decreased distance between ASM and epithelium, mucous gland and goblet cell hyperplasia, vascular changes and edema. Near these well known pathophysiological changes of the airways, the extracellular matrix (ECM) can be distinguished as a new important factor included in development of airway remodeling in asthma.

NCT ID: NCT03115632 Completed - Obesity Clinical Trials

Contributing Factors in the Pathobiology of Airway Remodeling in Obesity

Start date: April 9, 2018
Phase:
Study type: Observational

There are two aims for this study. The purpose of this study is to determine the effects of body weight and hormones on airway fibrosis (scarring) and lung function in obese & lean asthma subjects compared to obese & lean non-asthma subjects (Aim 1). And in obese subjects with asthma undergoing bariatric surgery compared to obese non-asthma subjects undergoing bariatric surgery (Aim 2).

NCT ID: NCT02648074 Completed - Allergic Asthma Clinical Trials

Eosinophil Induced Remodelling in Asthma

ERA
Start date: March 2014
Phase: N/A
Study type: Interventional

Asthma is a chronic, inflammatory disease of the lung characterized by intermittent airway obstruction, airway hyperresponsiveness, presence of activated inflammatory cells, inflammatory mediators, and airway structural changes. Airway smooth muscle (ASM) cells actively participate in the remodelling and inflammatory processes through proliferation, release of proinflammatory cytokines, chemokines, and extracellular matrix (ECM) proteins. Eosinophils as essential inflammatory cells may be of importance in ASM remodelling. It is known that eosinophil induces ASM cells proliferation via the secretion of cysteinyl leukotrienes in asthmatics. However there is a possible direct eosinophil-ASM cells functional interaction by adhesion processes. It has been shown that integrins modulate ASM proliferation and contractile protein expression demonstrating allergen-induced ASM remodelling in an animal model of allergic asthma. Wingless/integrase-1 (WNT) signaling regulates not only a wide range of developmental processes, but its aberrant activation can lead to disease. Recently, it was confirmed that genes polymorphisms in the WNT signaling pathway are associated with impaired lung function in childhood asthma. It was also found for the first time a relevant role of noncanonical WNT signaling in TGFβ-induced ECM expression by ASM cells and identified WNT-5A is the most abundant WNT ligand with increased expression in asthmatics. It demonstrates that WNT-5A could contribute to remodelling of the airways. Unfortunately, the effect of eosinophil on WNT secretion by ASM cells at present is unknown. Despite the widely acknowledged significance of eosinophils in asthma pathogenesis, the mechanism of eosinophil induced ASM remodelling is unsolved.

NCT ID: NCT02566291 Completed - Airway Remodeling Clinical Trials

Observational Study With Investigation of Two Second Generation Laryngeal Masks

OSSGA
Start date: January 2015
Phase: N/A
Study type: Observational

In a observational study the second-generation laryngeal masks LMA Supreme and Ambu AuraGain are investigated.

NCT ID: NCT01847768 Terminated - Asthma Clinical Trials

Human Rhinovirus Infection and Airway Remodeling Mediators

Start date: April 2013
Phase: N/A
Study type: Interventional

In this study, the following subjects will be exposed to human rhinovirus (HRV): - those with classification of mild-moderate asthma - healthy control subjects. The investigators will study the kinetics of HRV-induced inflammatory and remodeling responses in a well characterized group of asthmatic subjects and compare these outcomes to those in a healthy, non-asthmatic control group.

NCT ID: NCT01505933 Terminated - Airway Remodeling Clinical Trials

Airway Dimension Study in Children Undergoing MRI Sedated With Propofol and Dexmedetomidine

Start date: February 2012
Phase: Phase 2
Study type: Interventional

Sedation is required in infants and children to successfully complete MRI while maintaining respiratory and hemodynamic stability. Limited access to the patient may pose a safety risk during MRI examination. Therefore, appropriate drugs need to be selected, administered, and titrated to achieve these objectives. Propofol is commonly used for sedation in children in the MRI setting because of its predictability, rapid onset, and offset of action. Dexmedetomidine has sedative and analgesic properties without affecting cardiovascular and respiratory stability. The rationale of this research is to assess the effect of these drugs on the upper airway and validate their use in children with upper airway disorders.

NCT ID: NCT01230879 Terminated - Aging Clinical Trials

Effect of Ageing on Airway Remodeling

Start date: July 15, 2009
Phase: N/A
Study type: Interventional

The aim of the study is to investigate the relationship between aging and morphological changes in the lung. 120 consecutive healthy volunteers over 60 years will be enrolled for this trial.